Abstract：Objective: To investigate the regulatory effects of miR-653-5p on endometrial cancer and its related mechanisms. Methods: RT-qPCR was used to detect the levels of miR-653-5p in EC tumor tissues and cells.CCK-8,wound healing,and invasion assays were employed to evaluate the viability and metastasis of EC cells.Luciferase reporter gene assays were conducted to confirm the interaction between miR-653-5p and c-Myc.Western blotting was performed to detect the expression levels of c-Myc,p-IκBα,IκBα,p-NF-κB p65,and NF-κB p65 proteins.In vivo animal models were established by implanting EC cells overexpressing miR-653-5p to observe the tumor growth levels. Results: The RT-qPCR results indicated a decreased expression of miR-653-5p in EC tumor tissues and cells.Transfection with miR-653-5p mimics inhibited EC cell proliferation,suppressed cell cycle progression,promoted cell apoptosis,and reduced cell migration.Additionally,c-Myc may be a potential target of miR-653-5p,and overexpression of miR-653-5p altered cell proliferation,migration,and invasion by inhibiting the c-Myc and NF-κB pathways.Transfection with LV-miR-653-5p decreased the protein level of c-Myc and ultimately inhibited the growth of EC in vivo. Conclusion: miR-653-5p inhibits the survival and metastasis of EC cells by suppressing the c-Myc/NF-κB pathways.
陈华, 金全芳, 郝小姣, 黄骊莉, 吴嫣. miRNA-653-5p调控c-Myc/NF-κB通路对子宫内膜癌侵袭转移的影响[J]. 河北医学, 2025, 31(4): 537-543.
CHEN Hua, JIN Quanfang, HAO Xiaojiao, et al. Effect of miR-653-5p Regulation on the c-Myc/NF-κB Pathway in the Invasion and Metastasis of Endometrial Carcinoma. HeBei Med, 2025, 31(4): 537-543.
[1] Liao CI,Caesar MA,Lee D,et al.Increasing incidence of uterine carcinosarcoma:a united states cancer statistics study[J].Gynecol Oncol Rep,2022,40(2):100936. [2] Li N,Duan YH,Chen L,et al.Clinical significance of DNAH14 gene in uterine corpus endometrial carcinoma based on bioinformatics[J].Medical Data Mining,2022,5(3):17. [3] Basu A,Patel NG,Nicholson ED,et al.Spatiotemporal diversity and regulation of glycosaminoglycans in cell homeostasis and human disease[J].Am Physiol Cell Physiol,2022,322(5):849-864. [4] Peng TR,Lin HH,Yang LJ,et al.Effectiveness of glutamine in the management of oral mucositis in cancer patients:a meta-analysis of randomized controlled trials[J].Support Care Cancer,2021,29(8):4893. [5] Qiu P,Jie YK,Ma C,et al.Paired box 8 facilitates the c-MYC related cell cycle progress in TP53-mutation uterine corpus endometrial carcinoma through interaction with DDX5[J].Cell Death Discov,2022,8(1):276. [6] Zdrojkowskit,Jasinski T,Ferreira-Dias G,et al.The role of NF-κB in endometrial diseases in humans and animals:a review[J].Int Mol Sci,2023,24(3):2901. [7] Jin XX,GAo C,Wei WX,et al.The role of microRNA-4723-5p regulated by c-myc in triple-negative breast cancer[J].Bioengineered,2022,13(4):9097-9105. [8] Ye FZ,Liang YR,Wang YJ,et al.Cancer-associated fibroblasts facilitate breast cancer progression through exosomal circTBPL1-mediated intercellular communication[J].Cell Death Dis,2023,14(7):471. [9] Sadakierska-Chudy A.MicroRNAs:diverse mechanisms of action and their potential applications as cancer epi-therapeutics[J].Biomolecules,2020,10(9):1285. [10] Nothnick WB,Arachchige SP,Minchella P,et al.Targeting c-MYC:a potential non-hormonal therapeutic approach for endometriosis treatment[J].Front Cell Dev Biol,2023,11(21):1225055. [11] Pang YX,Bai GG,Zhao J,et al.The BRD4 inhibitor JQ1 suppresses tumor growth by reducing c-Myc expression in endometrial cancer[J].Transl Med,2022,20(1):336. [12] Zhang L,Shao GF,Shao JH,et al.PRMT5-activated c-Myc promote bladder cancer proliferation and invasion through up-regulating NF-κB pathway[J].Tissue Cell,2022,76(5):101788.
2025, Vol. 31 
冀公网安备13080202000786号